COVID-19 Clinical Trials and Expanded Access

Although recognized as an autoimmune disease the etiology of type 1 diabetes remainsunknown. Virus infections has been suggested as a possible agent triggering theautoimmune reaction finally resulting in beta-cell destruction and fate of insulinsecretion. SARS Cov-2 virus enters the infected cells by binding to the ACE-2 receptor,which is abundant in many tissues including the pancreas. Accordingly, SARS Covid-19infection may trigger the development of type 1 diabetes either by an activation of theimmune system or directly via beta-cell infection and destruction.Our aim is to study the impact of the Covid-19 epidemic on the development of type 1diabetes. This will be done in two ways: a clinical study and an epidemiological followup. During the next two years, adult patients with newly diagnosed type 1 diabetes willbe asked to participate. Type 1 diabetes will be diagnosed by usual means and a mixedmeal tolerance test will be performed at time of diagnosis and after one year to evaluatebeta-cell function. People with type 1 diabetes and serologically documented previousSARS Covid-19 will be compared with people with no previous infection regarding beta-cellfunction and fate of insulin secretion. In addition, we will estimate the number of newdiagnosed type 1 diabetes patients compared to previous years.

The Coronavirus has caused containment of more than a third of the world's population.Containment can drastically change lifestyle habits, including eating habits such as thenumber of meals, meal times or their composition. However, there is currently no data onthe influence of confinement on eating habits.

Bone and soft tissue sarcomas represent about 7-12% of all pediatric cancer and are aheterogeneous group of tumors arising in connective tissues embryologically derived fromthe mesenchyme. For some of these tumors relapse and mortality rates are stillsignificantly high. Therefore, further studies are needed to better understandpathogenetic processes underlying sarcomas to offer new and more effective treatments.Next generation sequencing (NGS) has opened new frontiers for cancer research allowing toidentify somatic or constitutional mutations known or yet unknown with the aim to betterunderstand carcinogenesis. The establishment of the genomic profile of the tumor couldalso help clinicians to personalize patients treatment based on their genetic andmolecular alterations.

Coronavirus has caused containment of more than half of the world's population and amajor and rapid reorganization of clinical and support services. The spread ofcoronavirus (COVID-19) has posed significant challenges for occupational health services.However, there is currently no data on the influence of this epidemic on the practice andfeelings of dental surgeons and associates

The physical inactivity promoted by the patient's hospitalization, including thoseinfected with the coronavirus, can lead to an important health impairment, includingatrophy and loss of muscle function. Thus, a prospective study will be conducted toassess the effect of a home-based exercise training program on health outcomes andquality of life in COVID-19 survivors.

A double-blind, randomized, controlled, clinical trial to evaluate the efficacy andsafety of MSC (mesenchymal stromal cells) intravenous administration in patients withCOVID-induced ARDS compared to a control arm.

With the results of this study the investigators aim to identify an effective treatmentthat will reduce morbidity and mortality of patients with symptomatic COVID-19 infection,which would in turn reduce the burden on the healthcare system by decreasing the need forintensive care.Objectives: The main objective of this research is to determine if once weekly treatmentwith the GLP-1 agonist semaglutide for 4 doses will reduce cardiac as well as non-cardiaccomplications of COVID-19 infection.Study Plan: The study design is prospective randomized open-label blinded-evaluation(PROBE). Eligible patients with symptomatic COVID-19 infection and an enhanced riskprofile as described above, who have been admitted to hospital due to symptoms ofCOVID-19 infection but do not as yet require critical care will be approached toparticipate in this study. Provided there are no exclusion criteria and the participantsagree by means of documented written informed consent, The participants the participantswill be randomized to receive s.c. semaglutide 0.25 mg s.c. or control immediately afterrandomization and then 0.5 mg s.c. at Day 7, Day 14 and Day 21. Blood will be drawn atDay 7±2 and Day 14±2 for the cardiac troponin biomarker and safety parameters. ECG willbe obtained at Day 7±2 and Day 14±2. Primary outcome will be assessed on Day 28.Primary outcome measure: A composite of (1) death from any cause or (2) mechanicalventilation (invasive or non-invasive) at 28 days.Major secondary outcome measure:(1) an elevation to >99th percentile URL upper reference limit (URL) in those with abaseline cardiac troponin level ≤99th percentile URL; or 3x elevation from baseline inthose with a baseline cardiac troponin >99th percentile URL; measured at 1 week (7-days)post randomization.Other major secondary outcome measure:A composite of 1. Death from any cause, mechanical ventilation or vasopressor or ECLS support at 28 days 2. an elevation to >99th percentile URL in those with a normal baseline troponin level; or 3x elevation from baseline in those with a baseline troponin; measured at 1 and 2 weeks (7±2 and 14±2 days) post randomization.

(a) Objectives 1. To assess the full lung function, exercise capacity, quality of life in patients with COVID-19 over 2 years. 2. To assess the longevity of the serology response to SARS-CoV2. 3. To investigate the association of the neutralization titer in plasma from different vaccinated cohorts to its protection of infection using in vivo model 4. To investigate the SARS-CoV-2 specific cellular and humoral immunities as well as their determinant factors from community subjects who have received different types of COVID-19 vaccines. 5. To assess the third booster dose for subjects who have poor antibody response despite having received two doses of CoronaVac (Sinovac)

The Coronavirus 2019 (COVID-19) pandemic has brought about unprecedented social, economicand mental-health challenges, especially for vulnerable populations such as pregnant andpost-partum females. In this study, we aimed to evaluate the relations between the fearof COVID-19 and postnatal depression symptoms.

Study population: Patients with fibrotic lung sequelae after recovery from acute phase ofsevere COVID19 pneumonia Objectives: To evaluate the effect of pirfenidone administeredfor 24 weeks in patients who have pulmonary fibrotic changes after suffering severeCOVID19 pneumonia, analysed by - % change in forced vital capacity (FVC) - % fibrosis in high resolution computed tomography (HRCT) of the lung